0001096906-17-000496.txt : 20170803 0001096906-17-000496.hdr.sgml : 20170803 20170803130202 ACCESSION NUMBER: 0001096906-17-000496 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 35 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170803 DATE AS OF CHANGE: 20170803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UTAH MEDICAL PRODUCTS INC CENTRAL INDEX KEY: 0000706698 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 870342734 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12575 FILM NUMBER: 171004078 BUSINESS ADDRESS: STREET 1: 7043 S 300 WEST CITY: MIDVALE STATE: UT ZIP: 84047 BUSINESS PHONE: 8015661200 10-Q 1 utah.htm 10Q
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 10‑Q

Quarterly Report Under Section 13 or 15(d) of
The Securities Exchange Act of 1934



For quarter ended: June 30, 2017
Commission File No. 001-12575


UTAH MEDICAL PRODUCTS, INC.
(Exact name of Registrant as specified in its charter)


UTAH
87‑0342734
(State or other jurisdiction of  incorporation or organization)
(I.R.S. Employer Identification No.)


7043 South 300 West
Midvale, Utah  84047
Address of principal executive offices


Registrant's telephone number:   (801) 566‑1200


 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and; (2) has been subject to such filing requirements for the past 90 days.   Yes ☒   No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer ☐
Accelerated filer ☒
Non-accelerated filer ☐
Smaller reporting company ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes ☐   No ☒

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).   Yes ☒  No ☐

Indicate the number of shares outstanding of each of the issuer's classes of common stock as of August 2, 2017: 3,719,000.
 
UTAH MEDICAL PRODUCTS, INC.
INDEX TO FORM 10‑Q

PART I - FINANCIAL INFORMATION 
  PAGE
     
Item 1.
Financial Statements
  
     
 
Consolidated Condensed Balance Sheets as of June 30, 2017 and December 31, 2016
1
     
 
Consolidated Condensed Statements of Income for the three and six months ended June 30, 2017 and June 30, 2016
2
     
 
Consolidated Condensed Statements of Cash Flows for six months ended June 30, 2017 and June 30, 2016
 3
     
 
Notes to Consolidated Condensed Financial Statements
4
     
Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
 6
     
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
13
     
Item 4.
Controls and Procedures
13
     
PART II – OTHER INFORMATION 
  
     
Item 1.
Legal Proceedings
14
     
Item 1A.
Risk Factors
14
     
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
15
     
Item 6.
Exhibits
16
     
SIGNATURES  
 17


PART I - FINANCIAL INFORMATION
  
Item 1.  Financial Statements
            
UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES
  
CONSOLIDATED CONDENSED BALANCE SHEETS AS OF
  
JUNE 30, 2017 AND DECEMBER 31, 2016
  
(in thousands)
  
   
     
(unaudited)
    
(audited)
  
ASSETS
  
JUNE 30,
2017
    
DECEMBER 31,
2016
  
             
Current assets:
            
 Cash
  
$
33,737
    
$
26,296
  
Investments, available-for-sale
    
72
      
64
  
Accounts & other receivables, net
    
4,473
      
3,211
  
Inventories
    
4,798
      
4,542
  
Other current assets
    
709
      
754
  
Total current assets
    
43,789
      
34,867
  
Property and equipment, net
    
10,145
      
9,966
  
Goodwill
    
13,822
      
13,487
  
Other intangible assets
    
33,529
      
31,947
  
Other intangible assets - accumulated amortization
    
(15,340
)
    
(13,683
)
Other intangible assets, net
    
18,189
      
18,264
  
Total assets
  
$
85,945
    
$
76,584
  
                 
LIABILITIES AND STOCKHOLDERS' EQUITY
                
Current liabilities:
                
Accounts payable
  
$
984
    
$
906
  
Accrued expenses
    
3,410
      
2,116
  
Total current liabilities
    
4,394
      
3,022
  
Deferred tax liability - intangible assets
    
3,178
      
3,209
  
Deferred income taxes
    
1,120
      
1,109
  
Total liabilities
    
8,692
      
7,340
  
                 
Stockholders' equity:
                
Preferred stock - $.01 par value; authorized - 5,000 shares; no shares issued or outstanding
                
Common stock - $.01 par value; authorized - 50,000 shares; issued - June 30, 2017, 3,718 shares and December 31, 2016, 3,713 shares
    
37
      
37
  
Accumulated other comprehensive income (loss)
    
(9,908
)
    
(12,243
)
Additional paid-in capital
    
615
      
378
  
Retained earnings
    
86,509
      
81,072
  
Total stockholders' equity
    
77,253
      
69,244
  
                 
Total liabilities and stockholders' equity
  
$
85,945
    
$
76,584
  
 
see notes to consolidated condensed financial statements
1
 
UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES
  
CONSOLIDATED CONDENSED STATEMENTS OF INCOME FOR THE
  
THREE AND SIX MONTHS ENDED JUNE 30, 2017 AND JUNE 30, 2016
  
(in thousands, except per share amounts - unaudited)
  
                         
    Three Months Ended     Six Months Ended  
    June 30,        June 30,  
   
2017
    
2016
    
2017
    
2016
  
Sales, net
  
$
10,829
    
$
10,490
    
$
21,088
    
$
20,791
  
                                 
Cost of goods sold
    
3,936
      
4,238
      
7,660
      
8,316
  
Gross profit
    
6,893
      
6,252
      
13,428
      
12,475
  
                                 
Operating expense
                                
Selling, general and administrative
    
1,740
      
1,818
      
3,432
      
3,619
  
Research & development
    
119
      
119
      
238
      
229
  
Total operating expenses
    
1,859
      
1,937
      
3,670
      
3,848
  
Operating income
    
5,034
      
4,315
      
9,758
      
8,627
  
                                 
Other income (expense)
    
23
      
64
      
49
      
165
  
Income before provision for income taxes
    
5,057
      
4,379
      
9,807
      
8,792
  
                                 
Provision for income taxes
    
1,187
      
1,120
      
2,402
      
2,316
  
Net income
  
$
3,870
    
$
3,259
    
$
7,405
    
$
6,476
  
                                 
Earnings per common share (basic)
  
$
1.04
    
$
0.87
    
$
1.99
    
$
1.72
  
                                 
Earnings per common share (diluted)
  
$
1.04
    
$
0.86
    
$
1.98
    
$
1.72
  
                                 
Shares outstanding - basic
    
3,716
      
3,758
      
3,715
      
3,756
  
                                 
Shares outstanding - diluted
    
3,732
      
3,776
      
3,732
      
3,773
  
                                 
Other comprehensive income (loss):
                                
Foreign currency translation net of taxes of $0 in all periods
  
$
1,675
    
$
(3,016
)
  
$
2,331
    
$
(3,426
)
Unrealized gain (loss) on investments net of taxes of $3, $0, $3 and ($4)
    
5
      
0
      
5
      
(6
)
Total comprehensive income
  
$
5,550
    
$
243
    
$
9,741
    
$
3,044
  
 
see notes to consolidated condensed financial statements
2
UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES
  
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
  
FOR THE SIX MONTHS ENDED JUNE 30, 2017 AND JUNE 30, 2016
  
(in thousands - unaudited)
  
   
    
Six Months Ended
 June 30,
  
   
2017
    
2016
  
CASH FLOWS FROM OPERATING ACTIVITIES:
            
Net income
  
$
7,405
    
$
6,476
  
Adjustments to reconcile net income to net cash provided by operating activities
                
Depreciation
    
330
      
298
  
Amortization
    
1,031
      
1,179
  
Provision for (recovery of) losses on accounts receivable
    
(1
)
    
(7
)
(Gain) loss on disposal of assets
    
-
      
-
  
Deferred income taxes
    
(182
)
    
(237
)
Stock-based compensation expense
    
69
      
42
  
Tax benefit attributable to exercise of stock options
    
21
      
35
  
 Changes in operating assets and liabilities:
                
Accounts receivable
    
(1,157
)
    
(450
)
Accrued interest and other receivables
    
(5
)
    
(34
)
Inventories
    
(100
)
    
196
  
Prepaid expenses and other current assets
    
60
      
61
  
Accounts payable
    
68
      
427
  
Accrued expenses
    
203
      
(222
)
Total adjustments
    
337
      
1,288
  
Net cash provided by operating activities
    
7,742
      
7,764
  
                 
CASH FLOWS FROM INVESTING ACTIVITIES:
                
Capital expenditures for:
                
Property and equipment
    
(114
)
    
(90
)
Intangible assets
    
-
      
(9
)
Net cash provided by (used in) investing activities
    
(114
)
    
(99
)
                 
CASH FLOWS FROM FINANCING ACTIVITIES:
                
Proceeds from issuance of common stock - options
    
168
      
257
  
Payment of dividends
    
(984
)
    
(976
)
Net cash provided by (used in) financing activities
    
(816
)
    
(719
)
                 
Effect of exchange rate changes on cash
    
629
      
(829
)
Net increase (decrease) in cash and cash equivalents
    
7,441
      
6,117
  
Cash at beginning of period
    
26,296
      
23,278
  
Cash at end of period
  
$
33,737
    
$
29,395
  
                 
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
                
Cash paid during the period for income taxes
  
$
2,676
    
$
2,422
  
Cash paid during the period for interest
    
0
      
0
  
 
see notes to consolidated condensed financial statements
3
UTAH MEDICAL PRODUCTS, INC.
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(unaudited)

(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States.  These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10‑K for the year ended December 31, 2016.  In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations.  Currency amounts are in thousands except per-share amounts and where noted.

(2) Recent Accounting Standards. In March 2016, new accounting guidance was issued to simplify several aspects of accounting for employee share-based payment (including stock option) transactions, including the accounting for income taxes, forfeitures and statutory tax withholding requirements, as well as classification in the statement of cash flows. Under the guidance, entities recognize all excess tax benefits and tax deficiencies as income tax expense or benefit in the income statement. UTMD adopted this standard on January 1, 2017, which had an insignificant impact on its consolidated financial statements. UTMD made a determination to continue to account for forfeitures by estimating the number of awards that are expected to vest.  Because UTMD primarily issues incentive stock options, excess tax benefits and tax deficiencies have historically been minimal.

In May 2014, new accounting guidance was issued that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract.  Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard.  This guidance becomes effective for annual reporting periods beginning after December 15, 2017 and early adoption is permitted for periods beginning after December 15, 2016. Because the vast majority of its revenue is recognized when a physical product is shipped, UTMD expects that the 2018 adoption of this standard will have an insignificant impact on its consolidated financial statements.

In February 2016, new accounting guidance was issued which requires recording most leases on the balance sheet. The new lease standard requires disclosure of key information about lease arrangements and aligns many of the underlying principles of this new model with those in the new revenue recognition standard noted above. This guidance becomes effective for annual reporting periods beginning after December 15, 2018, with early adoption permitted. UTMD has yet to assess the impact that this standard will have on its consolidated financial statements when it is adopted. The only significant lease the Company anticipates it will have at that time is for the parking lot at its Utah facility.

(3)  Inventories at June 30, 2017 and December 31, 2016 consisted of the following:
   
June 30,
    
December 31,
  
   
2017
    
2016
  
Finished goods
  
$
1,153
    
$
1,327
  
Work‑in‑process
    
1,260
      
942
  
Raw materials
    
2,385
      
2,273
  
Total
  
$
4,798
    
$
4,542
  

(4)  Stock-Based Compensation. At June 30, 2017, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors.  The Company accounts for stock compensation under FASB Accounting Standards Codification ("ASC") 718, Compensation - Stock Compensation.  This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors.  In the quarters ended June 30, 2017 and 2016, the Company recognized $33 and $21, respectively, in stock based compensation cost.  In the six months ended June 30, 2017 and 2016, the Company recognized $69 and $42, respectively, in stock based compensation cost.
4
(5)  Warranty Reserve.  The Company's published warranty is: "UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment.  During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price."
UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2016 or June 30, 2017.

(6)  Fair Value Measurements.  The Company follows ASC 820, Fair Value Measurement to determine fair value of its financial assets.  The following table provides financial assets carried at fair value measured as of June 30, 2017:
 
 
    
Fair Value Measurements Using
  
Description
Total Fair Value
at 6/30/2017
  
Quoted Prices
in Active Markets
for Identical Assets
(Level 1)
  
Significant Other
Observable Inputs
(Level 2)
  
Significant
Unobservable Inputs
(Level 3 )
  
Equities
  
$
72
    
$
72
    
$
0
    
$
0
  


(7)  Subsequent Events.  UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.

5
Item 2.  Management's Discussion and Analysis of Financial Condition and Results of Operations

General

Utah Medical Products, Inc. (UTMD) manufactures and markets a well-established range of specialty medical devices.  The Company's Form 10-K Annual Report for the year ended December 31, 2016 provides a detailed description of products, technologies, markets, regulatory issues, business initiatives, resources and business risks, among other details, and should be read in conjunction with this report.  Because of the relatively short span of time, results for any given three or six month period in comparison with a previous three or six month period may not be indicative of comparative results for the year as a whole.  Currency amounts in the report are in thousands, except per share amounts or where otherwise noted.  Currencies in this report are denoted as $ or USD = U.S. Dollars; A$ or AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros.

Analysis of Results of Operations

a) Overview

In the second calendar quarter (2Q) and first half (1H) of 2017, UTMD achieved results which suggest the Company may significantly exceed previously announced goals for 2017.

Income statement results in 2Q and 1H 2017 compared to the same periods of 2016 were as follows:

 
  
2Q 2017
    
2Q 2016
      
change
      
1H 2017
    
1H 2016
     change  
Net Sales
  
$
10,829
    
$
10,490
      
+3.2
%
  
$
21,088
    
$
20,791
      
+1.4
%
Gross Profit
    
6,893
      
6,252
      
+10.3
%
    
13,428
      
12,475
      
+7.6
%
Operating Income
    
5,034
      
4,315
      
+16.7
%
    
9,758
      
8,627
      
+13.1
%
Income Before Tax
    
5,057
      
4,379
      
+15.5
%
    
9,807
      
8,792
      
+11.5
%
Net Income
    
3,870
      
3,259
      
+18.7
%
    
7,405
      
6,476
      
+14.4
%
Earnings per Diluted Share
    
1.037
      
0.863
      
+20.2
%
    
1.985
      
1.716
      
+15.7
%

The change in value of the USD had a somewhat greater negative impact on 2Q and 1H 2017 Net Sales (revenues or sales) results as it did in the same periods in 2016 due primarily to the impact of BREXIT on the value of the GBP starting in late 2Q 2016. Revenues in 2Q 2017 and 1H 2017 would each have been about another 2% higher using the same foreign currency exchange (FX) rates as in the prior year (constant currency). UTMD's FX rates for income statement purposes are transaction-weighted averages. The average rates from the applicable foreign currency to USD during 2Q 2017 and 1H 2017 compared to the same periods in 2016 follow:

   
2Q 2017
    
2Q 2016
    
change
      
1H 2017
      
1H 2016
    
change
  
GBP
    
1.279
      
1.430
      
(10.6
%)
    
1.259
      
1.431
      
(12.0
%)
EUR
    
1.108
      
1.123
      
(1.3
%)
    
1.085
      
1.115
      
(2.7
%)
AUD
    
0.750
      
0.746
      
+0.6
%
    
0.755
      
0.736
      
+2.6
%
CAD    
0.743
      
n/a
              
0.749
      
n/a
          

UTMD's revenues invoiced in the above foreign currencies represented 30.9% of total consolidated USD sales in 2Q 2017 and 31.0% in 1H 2017.

The weighted average negative impact on GBP, EUR and AUD currency revenues in 2Q 2017 compared to 2Q 2016 was 5.0%, reducing reported USD sales by $132.  The weighted average negative impact on GBP, EUR and AUD currency sales in 1H 2017 compared to 1H 2016 was 5.7%, reducing reported USD sales by $301.  In constant currency terms, total consolidated 2Q 2017 sales were up 4.5%, and 1H 2017 sales were up 2.9%.

UTMD's consolidated Gross Profit Margin (GPM), Gross Profit (GP) divided by sales, improved to 63.7% primarily due to the conversion from distributor sales to direct end-user sales of the Filshie Clip System in France and Canada. Consolidated Operating Expenses (OE) were $78 lower in 2Q 2017 compared to 2Q 2016, and $177 lower in 1H 2017 compared to 1H 2016.  Included in G&A OE, the UK amortization of Identifiable Intangible Assets (IIA) was $62 lower in 2Q 2017 and $138 lower in 1H 2017 due to the weaker GBP, accounting for most of the change. The combination of lower OE and higher GPM spurred a 13% increase in 1H 2017 Operating Income (OI) with just a 1% increase in revenues. The 14% higher UTMD Net Income (NI) in 1H 2017 was a result of the 13% higher OI plus 1) a change in the income tax rate in the UK during 2Q 2017, and 2) a lower tax provision in the UK and Ireland based on translation of USD cash balances in those sovereignties when converted to their respective native currencies.
6

Earnings Per Diluted Share (EPS) in 1H 2017 were up 16% as a result of the 14% higher NI together with the benefit of 50,000 shares repurchased in 4Q 2016.  EPS for the most recent twelve months (TTM) were $3.49.
UTMD profit margins in 2Q 2017 and 1H 2017 compared to 2Q 2016 and 1H 2016 follow:
 
   
2Q 2017
(Apr-Jun)
    
2Q 2016
(Apr-Jun)
    
1H 2017
(Jan-Jun)
    
1H 2016
(Jan-Jun)
  
Gross Profit Margin (gross profit/ sales):
    
63.7
%
    
59.6
%
    
63.7
%
    
60.0
%
Operating Income Margin (operating income/ sales):
    
46.5
%
    
41.1
%
    
46.3
%
    
41.5
%
EBT Margin (profit before income taxes/ sales):
    
46.7
%
    
41.7
%
    
46.5
%
    
42.3
%
Net Income Margin (profit after taxes/ sales):
    
35.7
%
    
31.1
%
    
35.1
%
    
31.1
%

UTMD's Balance Sheet continued to strengthen. June 30, 2017 ending Cash and Investments were up $7.4 million and Stockholders' Equity was up $8.0 million from December 31, 2016.  FX rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of June 2017 and the end of December 2016 follow:

   
June 30,
2017
    
June 30,
2016
    
change
  
GBP
    
1.299
      
1.325
      
(2.0
%)
EUR
    
1.141
      
1.108
      
+3.0
%
AUD
    
0.768
      
0.744
      
+3.1
%
CAD
    
0.770
      
n/a
          

b) Revenues

The Company believes that revenue should be recognized at the time of shipment as title generally passes to the customer at the time of shipment, or completion of services performed under contract.  Revenue recognized by UTMD is based upon documented arrangements and fixed contracts in which the selling price is fixed prior to acceptance and completion of an order.  Revenue from product or service sales is generally recognized at the time the product is shipped or service completed and invoiced, and collectibility is reasonably assured.  Over 99% of UTMD's revenue is recognized at the time UTMD ships a physical medical device to a customer or a customer's designated inventory location, where the selling price for the item shipped was agreed prior to UTMD's acceptance and completion of the customer order. There are no post-shipment obligations which have been or are expected to be material to financial results.

There are circumstances under which revenue may be recognized when product is not shipped, which meet the criteria of SAB 104:  the Company provides engineering services, for example, design and production of manufacturing tooling that may be used in subsequent UTMD manufacturing of custom components for other companies.  This revenue is recognized when UTMD's service has been completed according to a fixed contractual agreement.

Terms of sale are established in advance of UTMD's acceptance of customer orders.  In the U.S., Canada, Ireland, UK, France and Australia, UTMD generally accepts orders directly from and ships directly to end user clinical facilities, as well as third party med/surg distributors, under UTMD's Standard Terms and Conditions (T&C) of Sale. About 14% of UTMD's U.S. domestic end user sales go through third party med/surg distributors which contract separately with clinical facilities to provide purchasing, storage and scheduled delivery functions for the applicable facility.  UTMD's T&C of Sale are substantially the same in the U.S., Canada, Ireland, UK, France and Australia.  In other geographic regions, UTMD sells its devices to third party distributors which then distribute the devices to medical facilities within their designated territories. UTMD's T&C of Sale for its international distributors are substantially the same.

UTMD may have separate discounted pricing agreements with a clinical facility or group of affiliated facilities based on volume of purchases.  Pricing agreements which are documented arrangements with clinical facilities, or groups of affiliated facilities, if applicable, are established in advance of orders accepted or shipments made.  For existing customers, past actual shipment volumes determine the fixed price by part number for the next agreement period of one year.  For new customers, the customer's best estimate of volume is accepted by UTMD for determining the ensuing fixed prices for the agreement period.  Except on rare occasions such as when customers do not meet prepayment agreements, prices are not adjusted after an order is accepted. For the sake of clarity, the separate pricing agreements with clinical facilities based on volume of purchases disclosure is not inconsistent with UTMD's disclosure above that the selling price is fixed prior to the acceptance of a specific customer order.
7

Total 2Q 2017 consolidated sales were $339 (3.2%) higher than in 2Q 2016, and in 1H 2017 were $297 (1.4%) higher than in 1H 2016.  Comparing 2Q 2017 to 2Q 2016, total U.S. domestic sales were 11% higher and USD sales outside the U.S. (OUS sales) were 3% lower.    Comparing 1H 2017 to 1H 2016, total U.S. domestic sales were 4% higher and OUS sales were 1% lower.

U.S. domestic sales, including direct sales to U.S. clinical facilities, OEM sales of components and finished devices to other companies, and sales of the Filshie Clip System to UTMD's exclusive U.S. distributor, CSI, were overall 11% ($511) and 4% ($435) higher in 2Q 2017 and 1H 2017, respectively, compared to 2Q 2016 and 1H 2016.  U.S. domestic sales are obviously not affected by FX rate fluctuations.   U.S. domestic sales were 49% of total consolidated sales in 2Q 2017 compared to 46% in 2Q 2016, and 50% in 1H 2017 compared to 48% in 1H 2016. Sales of Femcare's Filshie Clip System to CooperSurgical Inc. (CSI) for distribution in the U.S. were $366 higher in 2Q 2017 compared to 2Q 2016, and $330 higher in 1H 2017 compared to 1H 2016.  Femcare's sales to CSI were 23% of total domestic sales in 2Q 2017 compared to 17% in 2Q 2016, and 23% in 1H 2017 compared to 20% in 1H 2016. Domestic OEM sales were $59 (+8%) higher in 2Q 2017 compared to 2Q 2016, and $63 (+4%) higher in 1H 2017 compared to 1H 2016. Direct sales to U.S. user facilities were $85 (+3%) higher in 2Q 2017 compared to 2Q 2016, and $41 (+1%) higher in 1H 2017 compared to 1H 2016.

In 2Q 2017 and 1H 2017, OUS sales were lower due to the weaker GBP and fluctuation in international distributor purchases, despite the increased sales direct to end user facilities in Canada and France.
 
Trade sales are sales to third parties, excluding sales from one UTMD entity to another (intercompany sales).  Ireland subsidiary trade sales were 26% of OUS sales in 2Q 2017 compared to 36% of OUS sales in 2Q 2016.  Ireland subsidiary trade sales were 25% of OUS sales in 1H 2017 compared to 35% of OUS sales in 1H 2016.  The lower portion of OUS sales by Ireland was due primarily to the conversion from Ireland selling Filshie Sterishot kits to Canada and France distributors in 2016 (trade sales) to selling to other UTMD subsidiaries for direct distribution into Canada and France (intercompany sales) in 2017.

Trade sales by UTMD's UK subsidiary, Femcare-Nikomed Ltd. (Femcare UK), were 24% of OUS sales in both 2Q and 1H 2017 compared to 23% of OUS sales in 2Q 2016 and 25% in 1H 2016.  Included in the Femcare UK sales were the direct sales to end users in France which comprised 6% of OUS sales in 2Q 2017 and 5% of OUS sales in 1H 2017.  In other words, the increased direct sales from the UK to France offset the impact of the weaker GBP on all other UK trade sales.

Sales by UTMD's Australia subsidiary to Australia end user facilities were 11% of OUS sales in 2Q 2017 and 2Q 2016 as well as in 1H 2017 and 1H 2016.

Sales by UTMD's Canada subsidiary direct to Canada end user facilities were 15% of OUS sales in both 2Q 2017 and 1H 2017.

The following table provides USD sales amounts divided into general product categories for total sales and the subset of OUS sales:
Global revenues by product category:
 
   
2Q 2017
    
2Q 2016
      
1H 2017
      
1H 2016
  
Obstetrics
  
$
1,116
    
$
1,092
    
$
2,155
    
$
2,200
  
Gynecology/ Electrosurgery/ Urology
    
6,106
      
5,465
      
11,944
      
11,192
  
Neonatal
    
1,493
      
1,518
      
3,063
      
3,172
  
Blood Pressure Monitoring and Accessories*
    
2,114
      
2,415
      
3,926
      
4,227
  
Total:
  
$
10,829
    
$
10,490
    
$
21,088
    
$
20,791
  

OUS revenues by product category:
 
   
2Q 2017
    
2Q 2016
      
1H 2017
      
1H 2016
  
Obstetrics
  
$
216
    
$
132
    
$
360
    
$
313
  
Gynecology/ Electrosurgery/ Urology
    
3,717
      
3,474
      
7,276
      
6,827
  
Neonatal
    
479
      
576
      
997
      
1,189
  
Blood Pressure Monitoring and Accessories*
    
1,121
      
1,522
      
1,941
      
2,382
  
Total:
  
$
5,533
    
$
5,704
    
$
10,574
    
$
10,711
  
*includes molded components sold to OEM customers.

8
Looking forward to 2H 2017, sales are expected to grow faster than they did in 1H 2017 from 1) CSI forecasts indicate 50% higher Filshie purchases than in 2H 2016, 2) a weaker USD having a favorable USD conversion impact on foreign currency sales, and 3) Bayer has announced that as of September 2017, the Filshie Clip System's chief competing surgical contraceptive device, the Essure, will no longer be sold in the UK, Netherlands and Finland, places where UTMD has an established sales and marketing position.

c) Gross Profit (GP)

GP results from subtracting the cost of manufacturing and shipping products to customers (direct materials, direct labor, manufacturing overhead and shipping costs), or the purchase price of distributed finished products manufactured by other companies, from revenues.  At UTMD, manufacturing overhead costs fully absorb indirect costs including depreciation of manufacturing equipment and facilities, quality assurance, materials requirements planning and purchasing, manufacturing engineering, production supervision, shipping, royalties paid to other entities and health plan benefits for both direct and indirect manufacturing personnel.  UTMD's consolidated GP in 2Q 2017 was $641 higher than in 2Q 2016 while sales were only $339 higher.  UTMD's 1H 2017 GP was $954 higher than in 1H 2016 while sales were only $297 higher.   Manufacturing productivity was consistent with the prior year while direct sales in Canada and France at retail prices replaced distributor sales at wholesale prices in the prior year.

d) Operating Income (OI)

OI is GP minus OE comprised of general and administrative (G&A), sales and marketing (S&M) and product development (R&D) expenses. Consolidated USD-denominated OE were $1,859 in 2Q 2017 (17.2% of consolidated revenues) compared to $1,937 in 2Q 2016 (18.5% of consolidated revenues). Consolidated OE were $3,670 in 1H 2017 (17.4% of revenues) compared to $3,847 in 1H 2016 (18.5% of revenues).  In contrast to revenues, in the case of OE, lower FX rates were accretive to financial results. The OE of UTMD's foreign subsidiaries in the aggregate in 2Q 2017 and 1H 2017 would have been $90 and $200 higher, respectively, in constant currency.

Due to higher GP and lower OE, OI in 2Q 2017 and 1H 2017 was $5,034 and $9,758 respectively, compared to $4,315 and $8,627 in 2Q 2016 and 1H 2016 respectively. UTMD's 2Q and 1H 2017 continued excellent OIM was 46.5% and 46.3% respectively, compared to 41.1% and 41.5% in the same periods of 2016.

Consolidated S&M expenses in 2Q 2017 were $409 (3.8% of sales) compared to $457 (4.4% of sales) in 2Q 2016, and were $790 (3.8% of sales) in 1H 2017 compared to $862 (4.1% of sales) in 1H 2016.  S&M expenses include all customer support costs including training. In general, training is not required for UTMD's products since they are well-established and have been clinically widely used. Written "Instructions For Use" are packaged with all finished devices. Although UTMD does not have any explicit contracts with customers to provide training, it does have agreements in the U.S. and UK under which it agrees to provide hospital members inservice and clinical training as required and reasonably requested.

UTMD promises prospective customers that it will provide, at no charge in reasonable quantities, copies of instruction materials developed for the use of its products. UTMD provides customer support from offices in the U.S., Canada, the UK, Ireland and Australia by telephone, and employed representatives on a geographically dispersed basis, to answer user questions and help troubleshoot any user issues. Occasionally, on a case-by-case basis, UTMD may utilize the services of an independent practitioner to provide educational assistance to clinicians.  All inservice and training expenses are routinely expensed as they occur.  All of these services are allocated from S&M overhead costs included in OE.  Historically, marginal consulting costs have been immaterial to financial results.

R&D expenses in both 2Q 2017 and 2Q 2016 were $119 (1.1% of sales in both periods), and were $238 (1.1% of sales) in 1H 2017 compared to $229 (1.1% of sales) in 1H 2016.

Consolidated G&A expenses were $1,330 (12.3% of sales) in 2Q 2017 compared to $1,361 (13.0% of sales) in 2Q 2016, and were $2,643 (12.5% of sales) in 1H 2017 compared to $2,757 (13.3% of sales) in 1H 2016. Consolidated G&A expenses included non-cash expense from the amortization of IIA resulting from the Femcare acquisition of $510 (4.7% of consolidated revenues) in 2Q 2017 and $1,004 (4.8% of consolidated revenues) in 1H 2017, compared to $572 (5.4% of consolidated revenues) in 2Q 2016 and $1,148 (5.5% of consolidated revenues) in 1H 2016. The period to period differences in USD-denominated IIA amortization expense were predominantly FX-related since the IIA amortization expense was GBP 798 in 1H 2017 compared to GBP 802 in 1H 2016.
9

G&A expenses include the cost of outside financial auditors and corporate governance activities related to the implementation of SEC rules resulting from the Sarbanes-Oxley Act of 2002, as well as estimated stock-based compensation cost, a noncash expense. Option compensation expense included in G&A expenses was $33 in 2Q 2017 compared to $21 in 2Q 2016, and $69 in 1H 2017 compared to $42 in 1H 2016.

Summary comparison of (USD) consolidated operating expenses:
 
   
2Q 2017
    
2Q 2016
      
1H 2017
      
1H 2016
  
S&M Expense
  
$
410
    
$
457
    
$
790
    
$
862
  
R&D Expense
    
119
      
119
      
238
      
229
  
G&A Expense
    
1,330
      
1,361
      
2,642
      
2,757
  
Total Operating Expenses:
  
$
1,859
    
$
1,937
    
$
3,670
    
$
3,848
  

e) Non-operating expense (NOE)/ Non-operating income (NOI)

NOE/NOI includes the combination of 1) expenses from loan interest and bank fees; 2) expenses or income from losses or gains from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms; and 3) income from rent of underutilized property, investment income and royalties received from licensing the Company's technology. Negative NOE is NOI.  Net NOI in 2Q 2017 was $23 compared to $64 NOI in 2Q 2016. Net NOI in 1H 2017 was $49 compared to $165 NOI in 1H 2016. The loss/gain on remeasured foreign currency balances in 2Q 2017 was $0 compared to a gain of $38 in 2Q 2016.  In 1H 2017, the gain on remeasured foreign currency balances was $1 compared to a gain of $111 in 1H 2016.  Royalties received were $19 in 2Q 2017 compared to $22 in 2Q 2016, and $42 in 1H 2017 compared to $45 in 1H 2016.

f) Income Before Income Taxes (EBT)

Consolidated EBT results from subtracting net NOE or adding NOI from or to, as applicable, Consolidated OI.  Consolidated 2Q 2017 EBT was $5,057 (46.7% of sales) compared to $4,379 (41.7% of sales) in 2Q 2016. Consolidated 1H 2017 EBT was $9,807 (46.5% of sales) compared to $8,792 (42.3% of sales) in 1H 2016.

The EBT of Utah Medical Products, Inc. (U.S.) was $2,233 in 2Q 2017 compared to $2,144 in 2Q 2016, and $4,484 in 1H 2017 compared to $4,403 in 1H 2016. The EBT of Utah Medical Products, Ltd (Ireland) was EUR 875 in 2Q 2017 compared to EUR 931 in 2Q 2016, and EUR 1,512 in 1H 2017 compared to EUR 1,600 in 1H 2016 . The EBT of Femcare Group Ltd (Femcare-Nikomed, Ltd., UK and Femcare Australia) was GBP 1,146 in 2Q 2017 compared to GBP 817 in 2Q 2016, and GBP 2,306 in 1H 2017 compared to GBP 1,808 in 1H 2016.  The 2Q 2017 and 1H 2017 EBT of Utah Medical Products Canada, Inc. was CAD 567 and CAD 1,062, respectively.

Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, 2Q 2017 consolidated EBT excluding the remeasured bank balance currency gain or loss and interest expense (adjusted consolidated EBITDA) were $5,779 (53.4% of sales) compared to $5,098 (48.6% of sales) in 2Q 2016. Adjusted consolidated EBITDA in 1H 2017 were $11,236 (53.3% of sales) compared to $10,200 (49.1% of sales) in 1H 2016. Based on this performance, management now expects more than a $2 million increase in adjusted EBITDA for the 2017 year.  TTM adjusted EBITDA were $20,254.

g) Net Income (NI)

NI is EBT minus a provision for income taxes.  In addition to the growth in EBT, NI in 2017 was further leveraged by lower tax provisions. NI in 2Q 2017 of $3,870 was $611 (+19%) higher than the NI of $3,259 in 2Q 2016.  The consolidated income tax provision rate in 2Q 2017 was 23.5% compared to 25.6% for 2Q 2016.  NI in 1H 2017 of $7,405 was $930 (+14%) higher than the NI of $6,476 in 1H 2016. The consolidated income tax provision rates were 24.5% in 1H 2017 and 26.3% in 1H 2016.   On April 1, 2017, the corporate income tax rate in the UK was lowered from 20% to 19%. For foreign subsidiaries, the tax provision booked in consolidated results is based on taxable income in the applicable sovereignty, not based on U.S. GAAP EBT.  As UTMD held about $16 million in cash in USD currency in Ireland and UK subsidiary bank accounts as of June 30, 2017, and the USD weakened relative to the applicable native currency, the resulting translation loss for each subsidiary created a tax credit for those subsidiaries in their applicable native currencies. In summary, although there was not a corresponding translation loss for consolidated UTMD results, which are obviously expressed in USD, there was a tax provision benefit.
10
h) Earnings Per Share (EPS)

EPS are consolidated NI divided by the number of shares of stock outstanding (diluted to take into consideration stock option awards which are "in the money," i.e., have exercise prices below the applicable period's weighted average market value). Diluted EPS in 2Q 2017 were $1.037 compared to $0.863 in 2Q 2016.  In 1H 2017, EPS were $1.985 compared to $1.716 in 1H 2016.  With some help from lower diluted shares outstanding, 2Q 2017 EPS increased 20% (17.4 cents) compared to 2Q 2016, and 1H 2017 EPS increased 16% (26.9 cents) compared to 1H 2016. Looking forward, management is now projecting 2017 EPS greater than $3.60.

EPS for the most recent twelve months were $3.489, but this includes a 4Q 2016 "one-time" increase of $.033 from the adjustment in UTMD's deferred tax liability as a result of lower future income tax rates enacted in the UK in late 2016.

Diluted shares outstanding used to calculate 2Q 2017 EPS were 3,731,859 compared to 3,776,304 in 2Q 2016.  The number of shares added as a dilution factor in 2Q 2017 was 15,686 compared to 17,906 in 2Q 2016. Diluted shares outstanding used to calculate 1H 2017 EPS were 3,730,478 compared to 3,773,453 in 1H 2016.  The number of shares added as a dilution factor in 1H 2017 was 15,253 compared to 17,899 in 1H 2016. UTMD has not to date in 2017 repurchased any of its shares in the open market.  In 4Q 2016, UTMD repurchased 50,000 shares which accounts for the lower outstanding shares in 2Q 2017 and 1H 2017 compared to 2Q 2016 and 1H 2016.

Outstanding shares at the end of 2Q 2017 were 3,717,990 which included 1H 2017 employee and outside director option exercises of 4,860 shares.  The number of shares used for calculating earnings per share was higher than ending shares because of a time-weighted calculation of average outstanding shares plus dilution from unexercised employee and director options.  The total number of outstanding unexercised employee and outside director options at June 30, 2017 was 62,324 shares at an average exercise price of $46.15/ share, including shares awarded but not vested. This compares to 51,861 unexercised option shares outstanding at June 30, 2016 at an average exercise price of $39.59/ share. No option shares have been awarded to date in 2017.

During both 1H 2017 and 1H 2016, UTMD did not repurchase its shares in the open market. The Company retains the financial ability for repurchasing its shares when they seem undervalued. Based on the strong 1H 2017 financial performance, management must increase its beginning of year projection outlined in the 2016 SEC Form 10-K to an expectation of double-digit growth in NI and EPS for the 2017 year as a whole.

i) Return on Equity (ROE)

ROE is the portion of NI retained by UTMD to internally finance its growth, divided by the average accumulated stockholders' equity for the applicable time period.  Annualized ROE (before stockholder dividends) in 1H 2017 was 20% compared to 18% in 1H 2016.  The higher ROE in 1H 2017 was due to the increase in NI.  Targeting a high ROE of 20% remains a key financial objective for UTMD management.  ROE can be increased by increasing NI, or by reducing stockholders' equity by paying cash dividends to stockholders or by repurchasing shares.

Liquidity and Capital Resources

j) Cash flows

Net cash provided by operating activities, including adjustments for depreciation and amortization and other non-cash expenses along with changes in working capital, totaled $7,742 in 1H 2017 compared to $7,764 in 1H 2016.  The most significant differences in the two periods were the $930 increase in net income, a $707 use of cash from a larger increase in 1H 2017 trade accounts receivable compared to 1H 2016, a $426 benefit to cash from an increase in accrued expenses in 1H 2017 following a decrease in 1H 2016, and a $360 use of cash from a smaller increase in accounts payable in 1H 2017 compared to the same period in 2016.

Capital expenditures for property and equipment (PP&E) were $114 in 1H 2017 compared to $90 in 1H 2016.  Depreciation of PP&E was $330 in 1H 2017 compared to $298 in 1H 2016.
11

UTMD made cash dividend payments of $984 in 1H 2017 compared to $976 in 1H 2016.  The Company did not use cash to repurchase any of its own shares during either 1H 2017 or 1H 2016.

In 1H 2017, UTMD received $168 and issued 4,860 shares of its stock upon the exercise of employee and director stock options.  Option exercises in 1H 2017 were at an average price of $34.67 per share.  In comparison, in 1H 2016 the Company received $257 and issued 8,485 shares of stock on the exercise of employee and director stock options, net of 500 shares retired upon employees trading those shares in payment of the stock option exercise price. Option exercises in 1Q 2016 were at an average price of $32.06 per share.

Management believes that current cash balances, income from operations and effective management of working capital will provide the liquidity needed to finance internal growth plans. The Company may utilize cash not needed to support normal operations in one or a combination of the following:  1) in general, to continue to invest at an opportune time in ways that will enhance future profitability, for example, to fit-out a UK facility and property purchased in late 2016 specific to UTMD's needs; 2) to make additional investments in new technology and/or processes; and/or 3) to acquire a product line or company that will augment revenue and EPS growth and better utilize UTMD's existing infrastructure.  If there are no better strategic uses for UTMD's cash, the Company will continue to return cash to stockholders in the form of dividends and share repurchases when the stock appears undervalued.

k) Assets and Liabilities

June 30, 2017 total consolidated assets were $85,945, an increase of $9,361 from December 31, 2016. The increase was due mainly to a $7,450 increase in cash and investments. Other significant changes in assets included a $1,259 increase in consolidated net trade receivables, a $257 increase in consolidated inventories and a $260 increase in net intangible assets. UTMD's Ireland subsidiary EUR-denominated assets and liabilities were translated into USD at an FX rate 8.1% higher (stronger EUR) than the FX rate at the end of 2016. UTMD's UK subsidiary GBP-denominated assets were translated into USD at an FX rate 5.3% higher (stronger GBP) than the FX rate at the end of 2016.  UTMD's Australia subsidiary AUD-denominated assets were translated into USD at an FX rate 6.2% higher (stronger AUD) than the FX rate at the end of 2016.  The net book value of consolidated property, plant and equipment increased $179 at June 30, 2017 from the end of 2016 due to period-ending changed FX rates, $114 in new asset purchases and $330 in depreciation.

Working capital (current assets minus current liabilities) was $39,395 at June 30, 2017 compared to $31,845 at December 31, 2016.  A current asset increase of $8,922 was led by the $7,450 increase in cash and investments. Current liabilities increased $1,372, including a $1,294 increase in accrued liabilities. The accrued liabilities increase was mainly due to the $985 2Q 2017 quarterly dividend payment to stockholders accrued but not paid until July 6, whereas the $984 4Q 2016 dividend was paid before the end of December 2016.  UTMD management believes that its working capital remains sufficient to meet normal operating needs, new capital expenditures and projected cash dividend payments to stockholders.

June 30, 2017 intangible assets (goodwill plus other intangible assets) increased $260 from the end of 2016.  The increase was due to the higher FX rate for GBP Femcare intangibles as of June 30, 2017 compared to year-end 2016, offset somewhat by the $1,004 1H 2017 amortization of Femcare IIA.  At June 30, 2017, net intangible assets including goodwill declined to 37% of total consolidated assets compared to 41% at year-end 2016, and 43% at June 30, 2016.

The deferred tax liability balance for Femcare IIA ($9,084 on the date of the acquisition), was $3,178 at June 30, 2017 compared to $3,209 at December 31, 2016 and $3,784 at June 30, 2016.  Reduction of the deferred tax liability occurs as the book/tax difference of amortization is eliminated over the remaining useful life of the Femcare IIA. UTMD's total debt ratio (total liabilities/ total assets) as of June 30, 2017 was 10%, the same as at December 31, 2016.  UTMD's total debt ratio as of June 30, 2016 was 12%.

l) Management's Outlook

As outlined in its December 31, 2016 SEC 10-K report, UTMD's plan for 2017 is to
 
1)
continue to exploit distribution and manufacturing synergies by further integrating capabilities and resources in its multinational operations;
2)
introduce additional products helpful to clinicians through internal new product development;
3)
continue achieving excellent overall financial operating performance;
4)
utilize positive cash generation to  continue cash dividends to stockholders and make open market share repurchases if/when the UTMD share price seems undervalued; and
5)
be vigilant for accretive acquisition opportunities which may be increasingly brought about by difficult burdens on small, innovative companies.

12
Generally, the Company continues to effectively execute its plan as outlined above.  Based on results of 1H 2017, management expects to exceed the financial objectives for the full year of 2017 as stated in the Form SEC 10-K at the beginning of the year.

m) Accounting Policy Changes

Accounting Standards Update No. 2016-09, Improvements to Employee Share-Based Payment Accounting, was adopted by the Company effective January 1, 2017, as required by the ASU. This update to ASC 718, Compensation - Stock Compensation was issued by the Financial Accounting Standards Board as part of their simplification initiative.  This adoption had an immaterial impact on UTMD's retained earnings and other components of equity as of the date of adoption. In the statement of cash flows, the effect of the required change related to excess tax benefits, which was immaterial, was retrospectively applied. Stock compensation expense continues to reflect estimated forfeitures.

Forward-Looking Information.   This report contains certain forward-looking statements and information relating to the Company that are based on the beliefs of management as well as assumptions made by management based on information currently available.  When used in this document, the words "anticipate," "believe," "project," "estimate," "expect," "intend" and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements.  Such statements reflect the current view of the Company respecting future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties stated throughout the document.  Although the Company has attempted to identify important factors that could cause the actual results to differ materially, there may be other factors that cause the forward statement not to come true as anticipated, believed, projected, expected, or intended.  Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those described herein as anticipated, believed, projected, estimated, expected or intended.  Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and the Company assumes no obligation to update or disclose revisions to those estimates.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

UTMD has manufacturing and trading operations, including related assets, in the U.S. denominated in the U.S. Dollar (USD), in Ireland denominated in the Euro (EUR), in England denominated in the British Pound (GBP), in Australia denominated in the Australia Dollar (AUD), and, starting in 2017, in Canada denominated in the Canadian Dollar (CAD).  The currencies are subject to exchange rate fluctuations that are beyond the control of UTMD.  The exchange rates were .8763, .9474 and .9028 EUR per USD as of June 30, 2017, December 31, 2016 and June 30, 2016, respectively.  Exchange rates were .7696, .8105 and .7545 GBP per USD as of June 30, 2017, December 31, 2016 and June 30, 2016, respectively.  Exchange rates were 1.3028, 1.3829 and 1.3433 AUD per USD on June 30, 2017, December 31, 2016 and June 30, 2016, respectively.  Exchange rates were 1.2982 CAD per USD on June 30, 2017. UTMD manages its foreign currency risk without separate hedging transactions by either invoicing customers in the local currency where costs of production were incurred, by converting currencies as transactions occur, and by optimizing global account structures through liquidity management accounts.

Item 4. Controls and Procedures

The Company's management, under the supervision and with the participation of the Chief Executive Officer and the Principal Financial Officer, evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) as of June 30, 2017. Based on this evaluation, the Chief Executive Officer and Principal Financial Officer concluded that, as of June 30, 2017, the Company's disclosure controls and procedures were effective.
 
There were no changes in the Company's internal controls over financial reporting that occurred during the six months ended June 30, 2017, that have materially affected, or are reasonably likely to materially affect, the Company's internal controls over financial reporting.
13
PART II - OTHER INFORMATION

Item 1.  Legal Proceedings

The Company may be a party from time to time in litigation incidental to its business.  Presently, there is no litigation the outcome of which is expected to be material to financial results.

Item 1A.  Risk Factors

In addition to the other information set forth in this report, investors should carefully consider the factors discussed in Part I, "Item 1A. Risk Factors" in UTMD's Annual Report on Form 10-K for the year ended December 31, 2016, which could materially affect its business, financial condition or future results.  The risks described in the Annual Report on Form 10-K are not the only risks facing the Company.  Additional risks and uncertainties not currently known to UTMD or currently deemed to be immaterial also may materially adversely affect the Company's business, financial condition and/or operating results.

Legislative healthcare reform in the United States, as embodied in The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (the "Acts") added a substantial excise tax (MDET)  in 2013-2015 that  increased administrative costs and has led to decreased revenues in the U.S.:
The voluminous Acts, administrative rules to enforce the Acts and promised efforts to reform the Acts, make the U.S. medical device marketplace unpredictable, particularly for the thousands of small medical device manufacturers including UTMD that do not have the overhead structure that the larger medical device companies can afford.  Fortunately, the U.S. Congress has suspended the MDET for two years of 2016 and 2017.  To the extent that the Acts will in the future continue to place additional burdens on small medical device companies in the form of the excise tax on medical device sales, additional oversight of marketing and sales activities and new reporting requirements, the result is likely to continue to be negative for UTMD's ability to effectively compete and support continued investments in new product development and marketing of specialty devices in the U.S.

Increasing regulatory burdens including premarketing approval delays may result in significant loss of revenue, unpredictable costs and loss of management focus on helping the Company proactively conform with  requirements and thrive:
The Company's experience in 2001-2005, when the FDA improperly sought to shut it down, highlights the ongoing risk of being subject to a regulatory environment which can be arbitrary and capricious. The risks associated with such a circumstance relate not only to the substantial costs of litigation in millions of dollars, but also loss of business, the diversion of attention of key employees for an extended period of time, including new product development and routine quality control management activities, and a tremendous psychological and emotional toll on dedicated and diligent employees.

Since the FDA reserves to itself the interpretation of which vague industry standards comprise law at any point in time, it is impossible for any medical device manufacturer to ever be confident that it is operating within the Agency's version of the law.  The unconstitutional result is that companies, including UTMD, are considered guilty prior to proving their innocence.

Premarketing submission administrative burdens and substantial increases in "user fees" increase product development costs and result in delays to revenues from new or improved devices.  It recently took two and a half years to gain FDA approval of the use of a clearly safer single use Filshie Clip applicator, which had been in use for over seven years OUS, in lieu of a reused applicator approved in the U.S. since 1996, made of substantially equivalent materials for the same intended use applying the same implanted clip.

The growth of Group Purchasing Organizations (GPOs) adds non-productive costs, typically weakens the Company's marketing and sales efforts and may result in lower revenues:
GPOs, theoretically acting as bargaining agents for member hospitals, but actually collecting revenues from the companies that they are negotiating with, have made a concerted effort to turn medical devices that convey special patient safety advantages and better health outcomes, like UTMD's, into undifferentiated commodities. GPOs have been granted an antitrust exemption by the U.S. Congress. Otherwise, their business model based on "kickbacks" would be a violation of law.  These bureaucratic entities do not recognize or understand the overall cost of care as it relates to safety and effectiveness of devices, and they create a substantial administrative burden that is primarily related to collection of their administrative fees.

14
The Company's business strategy may not be successful in the future:
As the level of complexity and uncertainty in the medical device industry increases, evidenced, for example, by the unpredictable regulatory environment, the Company's views of the future and product/ market strategy may not yield financial results consistent with the past.

As the healthcare industry becomes increasingly bureaucratic it puts smaller companies like UTMD at a competitive disadvantage:
An aging population is placing greater burdens on healthcare systems, particularly hospitals. The length of time and number of administrative steps required in adopting new products for use in hospitals has grown substantially in recent years.  Smaller companies like UTMD typically do not have the administrative resources to deal with broad new administrative requirements, resulting in either loss of revenue or increased costs.  As UTMD introduces new products it believes are safer and more effective, it may find itself excluded from certain clinical users because of the existence of long term supply agreements for preexisting products, particularly from competitors which offer hospitals a broader range of products and services.  Restrictions used by hospital administrators to limit clinician involvement in device purchasing decisions makes communicating UTMD's clinical advantages much more difficult.

A product liability lawsuit could result in significant legal expenses and a large award against the Company:
UTMD's devices are frequently used in inherently risky situations to help physicians achieve a more positive outcome than what might otherwise be the case.  In any lawsuit where an individual plaintiff suffers permanent physical injury, the possibility of a large award for damages exists whether or not a causal relationship exists.

The Company's reliance on third party distributors in some markets may result in less predictable revenues:
UTMD's distributors have varying expertise in marketing and selling specialty medical devices.  They also sell other devices that may result in less focus on the Company's products.  In some countries, notably China, Pakistan and India not subject to similarly rigorous standards, by copying, a distributor of UTMD's products may eventually become a competitor with a cheaper but lower quality version of UTMD's devices.

The loss of one or more key employees could negatively affect UTMD performance:
In a small company with limited resources, the distraction or loss of key personnel at any point in time may be disruptive to performance.  The Company's benefits programs are key to recruiting and retaining talented employees.  An increase in UTMD's employee healthcare plan costs, for example, may cause the Company to have to reduce coverages which in turn represents a risk to retaining key employees.

Fluctuations in foreign currencies relative to the USD can result in significant differences in period to period financial results:
Since a significant portion of UTMD's sales are invoiced in foreign currencies and consolidated financial results are reported in USD terms, a stronger USD can have negative revenue effects. Conversely, a weaker USD would increase foreign subsidiary operating costs in USD terms. For the portion of sales to foreign entities made in fixed USD terms, a stronger USD makes the devices more expensive and weakens demand.  For the portion invoiced in a foreign currency, not only USD-denominated sales are reduced, but also gross profits may be reduced because finished distributed products and/or U.S. made raw materials and components are likely being purchased in fixed USD.

Future increases in sales of the Filshie Clip System due to Bayer stopping sales of the Essure device are uncertain, and may not materialize.

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds

UTMD did not purchase any of its own securities during 1H 2017.
15
Item 6.  Exhibits

Exhibit #
SEC Reference #
Title of Document
     
1
31
Certification of CEO pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
2
31
Certification of Principal Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
3
32
Certification of CEO pursuant to 18 U.S.C. §1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
4
32
Certification of Principal Financial Officer pursuant to 18 U.S.C. §1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
5
101 ins
XBRL Instance
     
6
101.sch
XBRL Schema
     
7
101.cal
XBRL Calculation
     
8
101.def
XBRL Definition
     
9
101.lab
XBRL Label
     
10
101.pre
XBRL Presentation

16

SIGNATURES

Pursuant to the requirements of the Securities Exchanges Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 
UTAH MEDICAL PRODUCTS, INC.
 
REGISTRANT
   
Date: 8/3/17
By: /s/ Kevin L. Cornwell
 
Kevin L. Cornwell
 
CEO
   
Date: 8/3/17
By: /s/ Paul O. Richins
 
Paul O. Richins
 
Principal Financial Officer
 

 
 
17

 
 EX-31.1 2 exh31_1.htm CERTIFICATION OF CEO PURSUANT TO RULE 13A-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
Exhibit 31.1

Exhibit 1
CERTIFICATION OF CEO
PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kevin L. Cornwell, certify that:

1.
I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.;
   
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   
(a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
   
(b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
   
(c)
evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
   
(d)
disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
   
5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
   
(a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
   
(b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 3, 2017


/s/ Kevin L. Cornwell
Kevin L. Cornwell
Chief Executive Officer
 
 
 
 EX-31.2 3 exh31_2.htm CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13A-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
Exhibit 31.2
Exhibit 2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Paul O. Richins, certify that:

1.
I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.;
   
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
   
4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   
(a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
   
(b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
   
(c)
evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
   
(d)
disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
   
5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
   
(a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
   
(b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 3, 2017


/s/ Paul O. Richins
Paul O. Richins
Principal Financial Officer
 EX-32.1 4 exh32_1.htm CERTIFICATION OF CEO PURSUANT TO 18 U.S.C. ?1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Exhibit 32.1
Exhibit 3
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Utah Medical Products, Inc. (the "Company") on Form 10-Q for the period ending June 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Kevin L. Cornwell, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1)
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.




/s/ Kevin L. Cornwell
Kevin L. Cornwell
Chief Executive Officer
August 3, 2017


A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
 
 
 EX-32.2 5 exh32_2.htm CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. ?1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Exhibit 32.2
Exhibit 4
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Utah Medical Products, Inc. (the "Company") on Form 10-Q for the period ending June 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Paul O. Richins, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1)
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.


/s/ Paul O. Richins
Paul O. Richins
Principal Financial Officer
August 3, 2017


A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.


 EX-101.INS 6 utmd-20170630.xml XBRL INSTANCE DOCUMENT 10-Q 2017-06-30 false UTAH MEDICAL PRODUCTS INC 0000706698 utmd --12-31 3719026 242289134 Accelerated Filer Yes No No 2017 Q2 72000 64000 4473000 3211000 709000 754000 43789000 34867000 10145000 9966000 13822000 13487000 33529000 31947000 15340000 13683000 18189000 18264000 85945000 76584000 984000 906000 3410000 2116000 4394000 3022000 3178000 3209000 1120000 1109000 8692000 7340000 37000 37000 -9908000 -12243000 615000 378000 86509000 81072000 77253000 69244000 85945000 76584000 0.01 0.01 5000000 5000000 0.01 0.01 50000000 50000000 3718000 3713000 3718000 3713000 10829000 10490000 21088000 20791000 3936000 4238000 7660000 8316000 6893000 6252000 13428000 12475000 1740000 1818000 3432000 3619000 119000 119000 238000 229000 1859000 1937000 3670000 3848000 5034000 4315000 9758000 8627000 23000 64000 49000 165000 5057000 4379000 9807000 8792000 1187000 1120000 2402000 2316000 3870000 3259000 1.04 0.87 1.99 1.72 1.04 0.86 1.98 1.72 3716000 3758000 3715000 3756000 3732000 3776000 3732000 3773000 1675000 -3016000 2331000 -3426000 5000 0 5000 -6000 5550000 243000 9741000 3044000 0 0 0 0 3000 0 3000 -4000 7405000 6476000 330000 298000 1031000 1179000 -1000 -7000 0 0 -182000 -237000 69000 42000 21000 35000 1157000 450000 5000 34000 100000 -196000 -60000 -61000 68000 427000 203000 -222000 337000 1288000 7742000 7764000 114000 90000 0 9000 -114000 -99000 168000 257000 984000 976000 -816000 -719000 629000 -829000 7441000 6117000 26296000 23278000 33737000 29395000 2676000 2422000 0 0 <!--egx--><p style='margin:0in;margin-bottom:.0001pt'>(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States.&#160; These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. (&quot;UTMD&quot; or &quot;the Company&quot;) annual report on Form 10 K for the year ended December 31, 2016.&#160; In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. &#160;Currency amounts are in thousands except per-share amounts and where noted.</p> <!--egx--><p style='margin:0in;margin-bottom:.0001pt'>(2) Recent Accounting Standards.</p> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin:0in;margin-bottom:.0001pt'>In March 2016, new accounting guidance was issued to simplify several aspects of accounting for employee share-based payment (including stock option) transactions, including the accounting for income taxes, forfeitures and statutory tax withholding requirements, as well as classification in the statement of cash flows. Under the guidance, entities recognize all excess tax benefits and tax deficiencies as income tax expense or benefit in the income statement. UTMD adopted this standard on January 1, 2017, which had an insignificant impact on its consolidated financial statements. UTMD made a determination to continue to account for forfeitures by estimating the number of awards that are expected to vest.&#160; Because UTMD primarily issues incentive stock options, excess tax benefits and tax deficiencies have historically been minimal.</p> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin:0in;margin-bottom:.0001pt'>In May 2014, new accounting guidance was issued that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.&nbsp; The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract.&nbsp; Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard.&nbsp; This guidance becomes effective for annual reporting periods beginning after December 15, 2017 and early adoption is permitted for periods beginning after December 15, 2016.&nbsp;Because the vast majority of its revenue is recognized when a physical product is shipped, UTMD expects that the 2018 adoption of this standard will have an insignificant impact on its consolidated financial statements.</p> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin:0in;margin-bottom:.0001pt'>In February 2016, new accounting guidance was issued which requires recording most leases on the balance sheet. The new lease standard requires disclosure of key information about lease arrangements and aligns many of the underlying principles of this new model with those in the new revenue recognition standard noted above. This guidance becomes effective for annual reporting periods beginning after December 15, 2018, with early adoption permitted. UTMD has yet to assess the impact that this standard will have on its consolidated financial statements when it is adopted. The only significant lease the Company anticipates it will have at that time is for the parking lot at its Utah facility. </p> <!--egx--><p style='margin:0in;margin-bottom:.0001pt'>(3) Inventories at June 30, 2017 and December 31, 2016 consisted of the following:</p> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" style='border-collapse:collapse'> <tr align="left"> <td width="192" valign="top" style='width:2.0in;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="144" valign="top" style='width:1.5in;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>June 30, 2017</p> </td> <td width="11" valign="top" style='width:8.5pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="135" valign="top" style='width:101.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>December 31, 2016</p> </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>Finished goods</p> </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="144" valign="top" style='width:1.5in;border:none;background:#CCEEFF;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>1,153</p> </td> <td width="11" valign="top" style='width:8.5pt;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="135" valign="top" style='width:101.0pt;border:none;background:#CCEEFF;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>1,327</p> </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>Work-in-process</p> </td> <td width="9" valign="top" style='width:6.5pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="144" valign="top" style='width:1.5in;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>1,260</p> </td> <td width="11" valign="top" style='width:8.5pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="135" valign="top" style='width:101.0pt;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>942</p> </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>Raw materials</p> </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="144" valign="top" style='width:1.5in;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>2,385</p> </td> <td width="11" valign="top" style='width:8.5pt;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="135" valign="top" style='width:101.0pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>2,273</p> </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>Total</p> </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:double windowtext 1.5pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="144" valign="top" style='width:1.5in;border:none;border-bottom:double windowtext 1.5pt;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>4,798</p> </td> <td width="11" valign="top" style='width:8.5pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:double windowtext 1.5pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="135" valign="top" style='width:101.0pt;border:none;border-bottom:double windowtext 1.5pt;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>4,542</p> </td> </tr> </table> <!--egx--><p style='margin:0in;margin-bottom:.0001pt'>(4) Stock-Based Compensation. At June 30, 2017, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors.&#160; The Company accounts for stock compensation under FASB Accounting Standards Codification (&#147;ASC&#148;) 718, <i>Compensation - Stock Compensation</i>.&#160; This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors.&#160; In the quarters ended June 30, 2017 and 2016, the Company recognized &#160;$33 and $21, respectively, in stock based compensation cost.&#160; In the six months ended June 30, 2017 and 2016, the Company recognized $69 and $42, respectively, in stock based compensation cost.</p> <!--egx--><p style='margin:0in;margin-bottom:.0001pt'>(5) Warranty Reserve.&#160; The Company&#146;s published warranty is: &#147;UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment.&#160; During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.&#148;</p> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin:0in;margin-bottom:.0001pt'>UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2016 or June 30, 2017.</p> <!--egx--><p style='margin:0in;margin-bottom:.0001pt;margin-bottom:6.0pt'>(6) Fair Value Measurements.&nbsp; The Company follows ASC 820, <i>Fair Value Measurement</i> to determine fair value of its financial assets.&#160; The following table provides financial assets carried at fair value measured as of June 30, 2017:</p> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" style='border-collapse:collapse'> <tr align="left"> <td width="96" valign="top" style='width:1.0in;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="12" valign="top" style='width:8.65pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="96" valign="top" style='width:1.0in;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="12" valign="top" style='width:8.65pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td colspan="8" valign="top" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Fair Value Measurements Using</p> </td> </tr> <tr align="left"> <td width="96" valign="bottom" style='width:1.0in;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>Description</p> </td> <td width="12" valign="top" style='width:8.65pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="96" valign="bottom" style='width:1.0in;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Total Fair Value</p> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>at 6/30/2017</p> </td> <td width="12" valign="top" style='width:8.65pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="115" valign="bottom" style='width:1.2in;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&#160;Quoted Prices</p> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>in Active Markets</p> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>for Identical Assets</p> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>(Level 1) </p> </td> <td width="12" valign="top" style='width:8.65pt;border:none;border-top:solid windowtext 1.0pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="115" valign="bottom" style='width:1.2in;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&#160;Significant Other</p> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Observable Inputs</p> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>(Level 2) </p> </td> <td width="12" valign="top" style='width:8.65pt;border:none;border-top:solid windowtext 1.0pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="115" valign="bottom" style='width:1.2in;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Significant</p> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Unobservable Inputs</p> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>(Level 3 ) </p> </td> </tr> <tr align="left"> <td width="96" valign="top" style='width:1.0in;border:none;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>Equities </p> </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="96" valign="top" style='width:1.0in;border:none;background:#CCEEFF;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>72</p> </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="115" valign="top" style='width:1.2in;border:none;background:#CCEEFF;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>72</p> </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="115" valign="top" style='width:1.2in;border:none;background:#CCEEFF;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>0</p> </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="115" valign="top" style='width:1.2in;border:none;background:#CCEEFF;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>0</p> </td> </tr> </table> <!--egx--><p style='margin:0in;margin-bottom:.0001pt'>&#160;(7) Subsequent Events.<b>&#160; </b>UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.</p> <!--egx--><p style='margin:0in;margin-bottom:.0001pt'>In March 2016, new accounting guidance was issued to simplify several aspects of accounting for employee share-based payment (including stock option) transactions, including the accounting for income taxes, forfeitures and statutory tax withholding requirements, as well as classification in the statement of cash flows. Under the guidance, entities recognize all excess tax benefits and tax deficiencies as income tax expense or benefit in the income statement. UTMD adopted this standard on January 1, 2017, which had an insignificant impact on its consolidated financial statements. UTMD made a determination to continue to account for forfeitures by estimating the number of awards that are expected to vest.&#160; Because UTMD primarily issues incentive stock options, excess tax benefits and tax deficiencies have historically been minimal.</p> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin:0in;margin-bottom:.0001pt'>In May 2014, new accounting guidance was issued that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.&nbsp; The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract.&nbsp; Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard.&nbsp; This guidance becomes effective for annual reporting periods beginning after December 15, 2017 and early adoption is permitted for periods beginning after December 15, 2016.&nbsp;Because the vast majority of its revenue is recognized when a physical product is shipped, UTMD expects that the 2018 adoption of this standard will have an insignificant impact on its consolidated financial statements.</p> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin:0in;margin-bottom:.0001pt'>In February 2016, new accounting guidance was issued which requires recording most leases on the balance sheet. The new lease standard requires disclosure of key information about lease arrangements and aligns many of the underlying principles of this new model with those in the new revenue recognition standard noted above. This guidance becomes effective for annual reporting periods beginning after December 15, 2018, with early adoption permitted. UTMD has yet to assess the impact that this standard will have on its consolidated financial statements when it is adopted. The only significant lease the Company anticipates it will have at that time is for the parking lot at its Utah facility.</p> <!--egx--><p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" style='border-collapse:collapse'> <tr align="left"> <td width="192" valign="top" style='width:2.0in;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="144" valign="top" style='width:1.5in;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>June 30, 2017</p> </td> <td width="11" valign="top" style='width:8.5pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="135" valign="top" style='width:101.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>December 31, 2016</p> </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>Finished goods</p> </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="144" valign="top" style='width:1.5in;border:none;background:#CCEEFF;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>1,153</p> </td> <td width="11" valign="top" style='width:8.5pt;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="135" valign="top" style='width:101.0pt;border:none;background:#CCEEFF;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>1,327</p> </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>Work-in-process</p> </td> <td width="9" valign="top" style='width:6.5pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="144" valign="top" style='width:1.5in;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>1,260</p> </td> <td width="11" valign="top" style='width:8.5pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="135" valign="top" style='width:101.0pt;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>942</p> </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>Raw materials</p> </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="144" valign="top" style='width:1.5in;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>2,385</p> </td> <td width="11" valign="top" style='width:8.5pt;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="135" valign="top" style='width:101.0pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>2,273</p> </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>Total</p> </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:double windowtext 1.5pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="144" valign="top" style='width:1.5in;border:none;border-bottom:double windowtext 1.5pt;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>4,798</p> </td> <td width="11" valign="top" style='width:8.5pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:double windowtext 1.5pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="135" valign="top" style='width:101.0pt;border:none;border-bottom:double windowtext 1.5pt;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>4,542</p> </td> </tr> </table> <!--egx--><p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" style='border-collapse:collapse'> <tr align="left"> <td width="96" valign="top" style='width:1.0in;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="12" valign="top" style='width:8.65pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="96" valign="top" style='width:1.0in;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="12" valign="top" style='width:8.65pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td colspan="8" valign="top" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Fair Value Measurements Using</p> </td> </tr> <tr align="left"> <td width="96" valign="bottom" style='width:1.0in;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>Description</p> </td> <td width="12" valign="top" style='width:8.65pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="96" valign="bottom" style='width:1.0in;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Total Fair Value</p> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>at 6/30/2017</p> </td> <td width="12" valign="top" style='width:8.65pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="115" valign="bottom" style='width:1.2in;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&#160;Quoted Prices</p> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>in Active Markets</p> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>for Identical Assets</p> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>(Level 1) </p> </td> <td width="12" valign="top" style='width:8.65pt;border:none;border-top:solid windowtext 1.0pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="115" valign="bottom" style='width:1.2in;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&#160;Significant Other</p> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Observable Inputs</p> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>(Level 2) </p> </td> <td width="12" valign="top" style='width:8.65pt;border:none;border-top:solid windowtext 1.0pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="115" valign="bottom" style='width:1.2in;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Significant</p> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Unobservable Inputs</p> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>(Level 3 ) </p> </td> </tr> <tr align="left"> <td width="96" valign="top" style='width:1.0in;border:none;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>Equities </p> </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="96" valign="top" style='width:1.0in;border:none;background:#CCEEFF;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>72</p> </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="115" valign="top" style='width:1.2in;border:none;background:#CCEEFF;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>72</p> </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="115" valign="top" style='width:1.2in;border:none;background:#CCEEFF;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>0</p> </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="115" valign="top" style='width:1.2in;border:none;background:#CCEEFF;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>0</p> </td> </tr> </table> 1153000 1327000 1260000 942000 2385000 2273000 4798000 4542000 33000 21000 69000 42000 72000 72000 0 0 0000706698 2015-12-31 0000706698 2016-06-30 0000706698 2016-12-31 0000706698 2017-01-01 2017-06-30 0000706698 2017-06-30 0000706698 2017-04-01 2017-06-30 0000706698 2016-04-01 2016-06-30 0000706698 2016-01-01 2016-06-30 0000706698 us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000706698 us-gaap:FairValueInputsLevel1Member 2017-06-30 0000706698 us-gaap:FairValueInputsLevel2Member 2017-06-30 0000706698 us-gaap:FairValueInputsLevel3Member 2017-06-30 0000706698 2017-08-02 iso4217:USD shares iso4217:USD shares EX-101.SCH 7 utmd-20170630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000140 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 000160 - Disclosure - Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables) link:presentationLink link:definitionLink link:calculationLink 000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW link:presentationLink link:definitionLink link:calculationLink 000150 - Disclosure - Inventories: Schedule of Inventory, Current (Tables) link:presentationLink link:definitionLink link:calculationLink 000090 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 000180 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 000110 - Disclosure - Warranty Reserve link:presentationLink link:definitionLink link:calculationLink 000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME link:presentationLink link:definitionLink link:calculationLink 000170 - Disclosure - Inventories: Schedule of Inventory, Current (Details) link:presentationLink link:definitionLink link:calculationLink 000190 - Disclosure - Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) link:presentationLink link:definitionLink link:calculationLink 000100 - Disclosure - Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 000070 - Disclosure - Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 000080 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles link:presentationLink link:definitionLink link:calculationLink 000120 - Disclosure - Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET link:presentationLink link:definitionLink link:calculationLink 000130 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 utmd-20170630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 utmd-20170630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 utmd-20170630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cash paid during the period for interest Accrued interest and other receivables Accrued interest and other receivables Adjustments to reconcile net income to net cash provided by operating activities: Common Stock, Shares Issued Retained earnings Document Fiscal Period Focus Fair Value, Inputs, Level 1 New Accounting Pronouncements and Changes in Accounting Principles Payment of dividends Payment of dividends Total adjustments Total adjustments Accrued expenses {1} Accrued expenses Selling, general and administrative Operating expense: Preferred Stock, Shares Issued Total current liabilities Total current liabilities LIABILITIES AND STOCKHOLDERS' EQUITY Other intangible assets, net Other intangible assets Policies Earnings per common share (basic) Total current assets Total current assets Entity Well-known Seasoned Issuer Current Fiscal Year End Date Document and Entity Information: Net cash provided by operating activities Net cash provided by operating activities Tax benefit attributable to exercise of stock options Stock-based compensation expense Income Statement Income Statement - Parenthetical Preferred Stock, Shares Outstanding Preferred stock - $.01 par value; authorized - 5,000 shares; no shares issued or outstanding Deferred tax liability - intangible assets Accounts & other receivables, net Equities Raw materials Finished goods Net cash provided by (used in) investing activities Net cash provided by (used in) investing activities Depreciation Operating income Operating income Income before provision for income taxes Income before provision for income taxes Accumulated other comprehensive income (loss) Current assets: Fair Value, Inputs, Level 3 Fair Value, Measurements, Recurring Schedule of Inventory, Current Stock-Based Compensation Capital expenditures for intangible assets Capital expenditures for intangible assets Deferred income taxes {1} Deferred income taxes Statement of Cash Flows Shares outstanding (diluted) Accrued expenses Current liabilities: Entity Current Reporting Status Fair Value, Measurement Frequency Details Subsequent Events Net increase (decrease) in cash and cash equivalents Net increase (decrease) in cash and cash equivalents Proceeds from issuance of common stock - options Total comprehensive income Total comprehensive income Unrealized gain (loss) on investments net of taxes of $3, $0, $3 and ($4) Net income Net income Total operating expense Total operating expense Total stockholders' equity Total stockholders' equity Investments, available-for-sale Entity Central Index Key Effect of exchange rate changes on cash Inventories {1} Inventories Sales, net Accounts payable Trading Symbol CASH FLOWS FROM OPERATING ACTIVITIES: TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Cash {1} Cash Cash at beginning of period Cash at end of period Entity Filer Category Entity Common Stock, Shares Outstanding Fair Value, Measurements, Fair Value Hierarchy Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis CASH FLOWS FROM INVESTING ACTIVITIES: Accounts payable {1} Accounts payable Changes in operating assets and liabilities: Provision for (recovery of) losses on accounts receivable Unrealized gain (loss) on investments tax adjustment Common Stock, Shares Authorized Stockholders' equity: Deferred income taxes TOTAL ASSETS TOTAL ASSETS Goodwill Statement of Financial Position Balance Sheets - Parenthetical Entity Voluntary Filers Document Type Measurement Frequency [Axis] Tables/Schedules New Accounting Pronouncements, Policy Accounts receivable Accounts receivable Shares outstanding (basic) Property and equipment, net Other current assets Document Fiscal Year Focus Statement [Line Items] Fair Value, Hierarchy [Axis] Fair Value Measurements Warranty Reserve Cash paid during the period for income taxes Net cash provided by (used in) financing activities Net cash provided by (used in) financing activities Foreign currency translation net of taxes of $0 in all periods Preferred Stock, Par Value Per Share Entity Public Float Document Period End Date Inventories {2} Inventories Notes Earnings per common share (diluted) Cost of goods sold Common Stock, Par Value Per Share Common stock - $.01 par value; authorized - 50,000 shares; issued - June 30, 2017, 3,718 shares and December 31, 2016, 3,713 shares Other intangible assets - accumulated amortization Other intangible assets - accumulated amortization Fair Value, Inputs, Level 2 Statement [Table] Basis of Presentation Capital expenditures for property and equipment Capital expenditures for property and equipment Other comprehensive income (loss): Research & development Common Stock, Shares Outstanding Inventories Total Amendment Flag Work-in-process CASH FLOWS FROM FINANCING ACTIVITIES: Provision for income taxes Additional paid-in capital TOTAL LIABILITIES TOTAL LIABILITIES ASSETS Entity Registrant Name Allocated Share-based Compensation Expense Prepaid expenses and other current assets Prepaid expenses and other current assets (Gain) loss on disposal of assets (Gain) loss on disposal of assets Amortization Foreign currency translation tax adjustment Other income (expense) Gross profit Gross profit Preferred Stock, Shares Authorized EX-101.PRE 11 utmd-20170630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.7.0.1
Document and Entity Information - USD ($)
 6 Months Ended
Jun. 30, 2017
Aug. 02, 2017
Document and Entity Information:    
Entity Registrant Name UTAH MEDICAL PRODUCTS INC  
Document Type 10-Q  
Document Period End Date Jun. 30, 2017  
Amendment Flag false  
Entity Central Index Key 0000706698  
Current Fiscal Year End Date --12-31  
Entity Common Stock, Shares Outstanding   3,719,026
Entity Public Float $ 242,289,134  
Entity Filer Category Accelerated Filer  
Entity Current Reporting Status Yes  
Entity Voluntary Filers No  
Entity Well-known Seasoned Issuer No  
Document Fiscal Year Focus 2017  
Document Fiscal Period Focus Q2  
Trading Symbol utmd  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.7.0.1
UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 31, 2016
Current assets:    
Cash $ 33,737 $ 26,296
Investments, available-for-sale 72 64
Accounts & other receivables, net 4,473 3,211
Inventories 4,798 4,542
Other current assets 709 754
Total current assets 43,789 34,867
Property and equipment, net 10,145 9,966
Goodwill 13,822 13,487
Other intangible assets 33,529 31,947
Other intangible assets - accumulated amortization (15,340) (13,683)
Other intangible assets, net 18,189 18,264
TOTAL ASSETS 85,945 76,584
Current liabilities:    
Accounts payable 984 906
Accrued expenses 3,410 2,116
Total current liabilities 4,394 3,022
Deferred tax liability - intangible assets 3,178 3,209
Deferred income taxes 1,120 1,109
TOTAL LIABILITIES 8,692 7,340
Stockholders' equity:    
Preferred stock - $.01 par value; authorized - 5,000 shares; no shares issued or outstanding
Common stock - $.01 par value; authorized - 50,000 shares; issued - June 30, 2017, 3,718 shares and December 31, 2016, 3,713 shares 37 37
Accumulated other comprehensive income (loss) (9,908) (12,243)
Additional paid-in capital 615 378
Retained earnings 86,509 81,072
Total stockholders' equity 77,253 69,244
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 85,945 $ 76,584
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.7.0.1
UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET (Parenthetical) - $ / shares
shares in Thousands
Jun. 30, 2017
Dec. 31, 2016
Statement of Financial Position    
Preferred Stock, Par Value Per Share $ 0.01 $ 0.01
Preferred Stock, Shares Authorized 5,000 5,000
Preferred Stock, Shares Issued
Preferred Stock, Shares Outstanding
Common Stock, Par Value Per Share $ 0.01 $ 0.01
Common Stock, Shares Authorized 50,000 50,000
Common Stock, Shares Issued 3,718 3,713
Common Stock, Shares Outstanding 3,718 3,713
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.7.0.1
UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Income Statement        
Sales, net $ 10,829 $ 10,490 $ 21,088 $ 20,791
Cost of goods sold 3,936 4,238 7,660 8,316
Gross profit 6,893 6,252 13,428 12,475
Operating expense:        
Selling, general and administrative 1,740 1,818 3,432 3,619
Research & development 119 119 238 229
Total operating expense 1,859 1,937 3,670 3,848
Operating income 5,034 4,315 9,758 8,627
Other income (expense) 23 64 49 165
Income before provision for income taxes 5,057 4,379 9,807 8,792
Provision for income taxes 1,187 1,120 2,402 2,316
Net income $ 3,870 $ 3,259 $ 7,405 $ 6,476
Earnings per common share (basic) $ 1.04 $ 0.87 $ 1.99 $ 1.72
Earnings per common share (diluted) $ 1.04 $ 0.86 $ 1.98 $ 1.72
Shares outstanding (basic) 3,716 3,758 3,715 3,756
Shares outstanding (diluted) 3,732 3,776 3,732 3,773
Other comprehensive income (loss):        
Foreign currency translation net of taxes of $0 in all periods $ 1,675 $ (3,016) $ 2,331 $ (3,426)
Unrealized gain (loss) on investments net of taxes of $3, $0, $3 and ($4) 5 0 5 (6)
Total comprehensive income $ 5,550 $ 243 $ 9,741 $ 3,044
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.7.0.1
UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME (Parenthetical) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Income Statement        
Foreign currency translation tax adjustment $ 0 $ 0 $ 0 $ 0
Unrealized gain (loss) on investments tax adjustment $ 3 $ 0 $ 3 $ (4)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.7.0.1
UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income $ 7,405 $ 6,476
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation 330 298
Amortization 1,031 1,179
Provision for (recovery of) losses on accounts receivable (1) (7)
(Gain) loss on disposal of assets 0 0
Deferred income taxes (182) (237)
Stock-based compensation expense 69 42
Tax benefit attributable to exercise of stock options 21 35
Changes in operating assets and liabilities:    
Accounts receivable (1,157) (450)
Accrued interest and other receivables (5) (34)
Inventories (100) 196
Prepaid expenses and other current assets 60 61
Accounts payable 68 427
Accrued expenses 203 (222)
Total adjustments 337 1,288
Net cash provided by operating activities 7,742 7,764
CASH FLOWS FROM INVESTING ACTIVITIES:    
Capital expenditures for property and equipment (114) (90)
Capital expenditures for intangible assets 0 (9)
Net cash provided by (used in) investing activities (114) (99)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from issuance of common stock - options 168 257
Payment of dividends (984) (976)
Net cash provided by (used in) financing activities (816) (719)
Effect of exchange rate changes on cash 629 (829)
Net increase (decrease) in cash and cash equivalents 7,441 6,117
Cash at beginning of period 26,296 23,278
Cash at end of period 33,737 29,395
Cash paid during the period for income taxes 2,676 2,422
Cash paid during the period for interest $ 0 $ 0
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.7.0.1
Basis of Presentation
 6 Months Ended
Jun. 30, 2017
Notes  
Basis of Presentation

(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States.  These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10 K for the year ended December 31, 2016.  In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations.  Currency amounts are in thousands except per-share amounts and where noted.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.7.0.1
New Accounting Pronouncements and Changes in Accounting Principles
 6 Months Ended
Jun. 30, 2017
Notes  
New Accounting Pronouncements and Changes in Accounting Principles

(2) Recent Accounting Standards.

 

In March 2016, new accounting guidance was issued to simplify several aspects of accounting for employee share-based payment (including stock option) transactions, including the accounting for income taxes, forfeitures and statutory tax withholding requirements, as well as classification in the statement of cash flows. Under the guidance, entities recognize all excess tax benefits and tax deficiencies as income tax expense or benefit in the income statement. UTMD adopted this standard on January 1, 2017, which had an insignificant impact on its consolidated financial statements. UTMD made a determination to continue to account for forfeitures by estimating the number of awards that are expected to vest.  Because UTMD primarily issues incentive stock options, excess tax benefits and tax deficiencies have historically been minimal.

 

In May 2014, new accounting guidance was issued that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract.  Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard.  This guidance becomes effective for annual reporting periods beginning after December 15, 2017 and early adoption is permitted for periods beginning after December 15, 2016. Because the vast majority of its revenue is recognized when a physical product is shipped, UTMD expects that the 2018 adoption of this standard will have an insignificant impact on its consolidated financial statements.

 

In February 2016, new accounting guidance was issued which requires recording most leases on the balance sheet. The new lease standard requires disclosure of key information about lease arrangements and aligns many of the underlying principles of this new model with those in the new revenue recognition standard noted above. This guidance becomes effective for annual reporting periods beginning after December 15, 2018, with early adoption permitted. UTMD has yet to assess the impact that this standard will have on its consolidated financial statements when it is adopted. The only significant lease the Company anticipates it will have at that time is for the parking lot at its Utah facility.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.7.0.1
Inventories
 6 Months Ended
Jun. 30, 2017
Notes  
Inventories

(3) Inventories at June 30, 2017 and December 31, 2016 consisted of the following:

 

 

 

June 30, 2017

 

 

December 31, 2016

Finished goods

$

1,153

 

$

1,327

Work-in-process

 

1,260

 

 

942

Raw materials

 

2,385

 

 

2,273

Total

$

4,798

 

$

4,542
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock-Based Compensation
 6 Months Ended
Jun. 30, 2017
Notes  
Stock-Based Compensation

(4) Stock-Based Compensation. At June 30, 2017, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors.  The Company accounts for stock compensation under FASB Accounting Standards Codification (“ASC”) 718, Compensation - Stock Compensation.  This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors.  In the quarters ended June 30, 2017 and 2016, the Company recognized  $33 and $21, respectively, in stock based compensation cost.  In the six months ended June 30, 2017 and 2016, the Company recognized $69 and $42, respectively, in stock based compensation cost.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.7.0.1
Warranty Reserve
 6 Months Ended
Jun. 30, 2017
Notes  
Warranty Reserve

(5) Warranty Reserve.  The Company’s published warranty is: “UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment.  During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.”

 

UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2016 or June 30, 2017.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.7.0.1
Fair Value Measurements
 6 Months Ended
Jun. 30, 2017
Notes  
Fair Value Measurements

(6) Fair Value Measurements.  The Company follows ASC 820, Fair Value Measurement to determine fair value of its financial assets.  The following table provides financial assets carried at fair value measured as of June 30, 2017:

 

 

 

 

 

 

Fair Value Measurements Using

Description

 

 

Total Fair Value

at 6/30/2017

 

 

 Quoted Prices

in Active Markets

for Identical Assets

(Level 1)

 

 

 Significant Other

Observable Inputs

(Level 2)

 

 

Significant

Unobservable Inputs

(Level 3 )

Equities

 

$

72

 

$

72

 

$

0

 

$

0
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.7.0.1
Subsequent Events
 6 Months Ended
Jun. 30, 2017
Notes  
Subsequent Events

 (7) Subsequent Events.  UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.7.0.1
New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)
 6 Months Ended
Jun. 30, 2017
Policies  
New Accounting Pronouncements, Policy

In March 2016, new accounting guidance was issued to simplify several aspects of accounting for employee share-based payment (including stock option) transactions, including the accounting for income taxes, forfeitures and statutory tax withholding requirements, as well as classification in the statement of cash flows. Under the guidance, entities recognize all excess tax benefits and tax deficiencies as income tax expense or benefit in the income statement. UTMD adopted this standard on January 1, 2017, which had an insignificant impact on its consolidated financial statements. UTMD made a determination to continue to account for forfeitures by estimating the number of awards that are expected to vest.  Because UTMD primarily issues incentive stock options, excess tax benefits and tax deficiencies have historically been minimal.

 

In May 2014, new accounting guidance was issued that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract.  Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard.  This guidance becomes effective for annual reporting periods beginning after December 15, 2017 and early adoption is permitted for periods beginning after December 15, 2016. Because the vast majority of its revenue is recognized when a physical product is shipped, UTMD expects that the 2018 adoption of this standard will have an insignificant impact on its consolidated financial statements.

 

In February 2016, new accounting guidance was issued which requires recording most leases on the balance sheet. The new lease standard requires disclosure of key information about lease arrangements and aligns many of the underlying principles of this new model with those in the new revenue recognition standard noted above. This guidance becomes effective for annual reporting periods beginning after December 15, 2018, with early adoption permitted. UTMD has yet to assess the impact that this standard will have on its consolidated financial statements when it is adopted. The only significant lease the Company anticipates it will have at that time is for the parking lot at its Utah facility.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.7.0.1
Inventories: Schedule of Inventory, Current (Tables)
 6 Months Ended
Jun. 30, 2017
Tables/Schedules  
Schedule of Inventory, Current

 

 

 

June 30, 2017

 

 

December 31, 2016

Finished goods

$

1,153

 

$

1,327

Work-in-process

 

1,260

 

 

942

Raw materials

 

2,385

 

 

2,273

Total

$

4,798

 

$

4,542
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.7.0.1
Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables)
 6 Months Ended
Jun. 30, 2017
Tables/Schedules  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

 

 

 

 

 

 

Fair Value Measurements Using

Description

 

 

Total Fair Value

at 6/30/2017

 

 

 Quoted Prices

in Active Markets

for Identical Assets

(Level 1)

 

 

 Significant Other

Observable Inputs

(Level 2)

 

 

Significant

Unobservable Inputs

(Level 3 )

Equities

 

$

72

 

$

72

 

$

0

 

$

0
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.7.0.1
Inventories: Schedule of Inventory, Current (Details) - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 31, 2016
Details    
Finished goods $ 1,153 $ 1,327
Work-in-process 1,260 942
Raw materials 2,385 2,273
Total $ 4,798 $ 4,542
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock-Based Compensation (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Details        
Allocated Share-based Compensation Expense $ 33 $ 21 $ 69 $ 42
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.7.0.1
Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)
$ in Thousands
Jun. 30, 2017
USD ($)
Fair Value, Inputs, Level 1  
Equities $ 72
Fair Value, Inputs, Level 2  
Equities 0
Fair Value, Inputs, Level 3  
Equities 0
Fair Value, Measurements, Recurring  
Equities $ 72
EXCEL 31 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 32 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 33 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 35 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 13 108 1 false 4 0 false 3 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://www.utahmed.com/20170630/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET Sheet http://www.utahmed.com/20170630/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET Statements 2 false false R3.htm 000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET (Parenthetical) Sheet http://www.utahmed.com/20170630/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEETParenthetical UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET (Parenthetical) Statements 3 false false R4.htm 000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME Sheet http://www.utahmed.com/20170630/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOMEANDCOMPREHENSIVEINCOME UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME Statements 4 false false R5.htm 000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME (Parenthetical) Sheet http://www.utahmed.com/20170630/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOMEParenthetical UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME (Parenthetical) Statements 5 false false R6.htm 000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW Sheet http://www.utahmed.com/20170630/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW Statements 6 false false R7.htm 000070 - Disclosure - Basis of Presentation Sheet http://www.utahmed.com/20170630/role/idr_DisclosureBasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 000080 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles Sheet http://www.utahmed.com/20170630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples New Accounting Pronouncements and Changes in Accounting Principles Notes 8 false false R9.htm 000090 - Disclosure - Inventories Sheet http://www.utahmed.com/20170630/role/idr_DisclosureInventories Inventories Notes 9 false false R10.htm 000100 - Disclosure - Stock-Based Compensation Sheet http://www.utahmed.com/20170630/role/idr_DisclosureStockBasedCompensation Stock-Based Compensation Notes 10 false false R11.htm 000110 - Disclosure - Warranty Reserve Sheet http://www.utahmed.com/20170630/role/idr_DisclosureWarrantyReserve Warranty Reserve Notes 11 false false R12.htm 000120 - Disclosure - Fair Value Measurements Sheet http://www.utahmed.com/20170630/role/idr_DisclosureFairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 000130 - Disclosure - Subsequent Events Sheet http://www.utahmed.com/20170630/role/idr_DisclosureSubsequentEvents Subsequent Events Notes 13 false false R14.htm 000140 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies) Sheet http://www.utahmed.com/20170630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies) Policies http://www.utahmed.com/20170630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples 14 false false R15.htm 000150 - Disclosure - Inventories: Schedule of Inventory, Current (Tables) Sheet http://www.utahmed.com/20170630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables Inventories: Schedule of Inventory, Current (Tables) Tables 15 false false R16.htm 000160 - Disclosure - Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables) Sheet http://www.utahmed.com/20170630/role/idr_DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTables Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables) Tables 16 false false R17.htm 000170 - Disclosure - Inventories: Schedule of Inventory, Current (Details) Sheet http://www.utahmed.com/20170630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails Inventories: Schedule of Inventory, Current (Details) Details http://www.utahmed.com/20170630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables 17 false false R18.htm 000180 - Disclosure - Stock-Based Compensation (Details) Sheet http://www.utahmed.com/20170630/role/idr_DisclosureStockBasedCompensationDetails Stock-Based Compensation (Details) Details http://www.utahmed.com/20170630/role/idr_DisclosureStockBasedCompensation 18 false false R19.htm 000190 - Disclosure - Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Sheet http://www.utahmed.com/20170630/role/idr_DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Details http://www.utahmed.com/20170630/role/idr_DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTables 19 false false All Reports Book All Reports utmd-20170630.xml utmd-20170630.xsd utmd-20170630_cal.xml utmd-20170630_def.xml utmd-20170630_lab.xml utmd-20170630_pre.xml true true ZIP 37 0001096906-17-000496-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001096906-17-000496-xbrl.zip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end